Urinary excretion of pyridinium crosslinks in short children treated with growth hormone

Francesco Branca, A. Spagnoli, S. Cianfarani, G. Spadoni, M. H N Golden, B. Boscherini, S. Valtueña, S. P. Robins

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this study was to evaluate the effect of growth hormone (GH) treatment on bone resorption in children with GH deficiency and those with idiopathic short stature. The study population included seven children with subnormal spontaneous GH secretion and 13 children with idiopathic short stature, all of them pre-pubertal. Anthropometric measurements, free, protein-bound and total urinary pyridinoline (Pyd) and deoxypyridinoline (Dpd), serum GH, and serum immunoreactive PTH were measured at baseline and months 1, 3, 6 and 12 of GH treatment. The urinary excretion of total Pyd and Dpd, standardized by the cube of height (m3) in overnight, 24-hour urine collections was not different from age-matched healthy controls at baseline in either group of patients. During treatment with human recombinant GH, both pyridinium crosslinks increased above normal values, reaching a peak after one month in children with GH deficiency and later (after 3-6 months) in children with short stature. Free and total crosslink forms were correlated, and GH treatment did not affect the proportion of free to bound crosslinks. Serum concentrations of iPTH showed a moderate but not statistically significant increase. This study provides no evidence of reduced bone resorption in untreated GH deficiency or in idiopathic short stature. GH treatment induced a marked, but temporary, increase of bone resorption in both groups of patients.

Original languageEnglish
Pages (from-to)27-34
Number of pages8
JournalJournal of Pediatric Endocrinology and Metabolism
Volume15
Issue number1
Publication statusPublished - 2002

Fingerprint

Growth Hormone
Bone Resorption
Serum
Therapeutics
Urine Specimen Collection
Human Growth Hormone
Reference Values
Population

Keywords

  • Bone metabolism
  • Deoxypyridinoline
  • Growth hormone
  • PTH
  • Pyridinoline

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Branca, F., Spagnoli, A., Cianfarani, S., Spadoni, G., Golden, M. H. N., Boscherini, B., ... Robins, S. P. (2002). Urinary excretion of pyridinium crosslinks in short children treated with growth hormone. Journal of Pediatric Endocrinology and Metabolism, 15(1), 27-34.

Urinary excretion of pyridinium crosslinks in short children treated with growth hormone. / Branca, Francesco; Spagnoli, A.; Cianfarani, S.; Spadoni, G.; Golden, M. H N; Boscherini, B.; Valtueña, S.; Robins, S. P.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 15, No. 1, 2002, p. 27-34.

Research output: Contribution to journalArticle

Branca, F, Spagnoli, A, Cianfarani, S, Spadoni, G, Golden, MHN, Boscherini, B, Valtueña, S & Robins, SP 2002, 'Urinary excretion of pyridinium crosslinks in short children treated with growth hormone', Journal of Pediatric Endocrinology and Metabolism, vol. 15, no. 1, pp. 27-34.
Branca, Francesco ; Spagnoli, A. ; Cianfarani, S. ; Spadoni, G. ; Golden, M. H N ; Boscherini, B. ; Valtueña, S. ; Robins, S. P. / Urinary excretion of pyridinium crosslinks in short children treated with growth hormone. In: Journal of Pediatric Endocrinology and Metabolism. 2002 ; Vol. 15, No. 1. pp. 27-34.
@article{384e19364a4d4a66bf078015e5a5787e,
title = "Urinary excretion of pyridinium crosslinks in short children treated with growth hormone",
abstract = "The aim of this study was to evaluate the effect of growth hormone (GH) treatment on bone resorption in children with GH deficiency and those with idiopathic short stature. The study population included seven children with subnormal spontaneous GH secretion and 13 children with idiopathic short stature, all of them pre-pubertal. Anthropometric measurements, free, protein-bound and total urinary pyridinoline (Pyd) and deoxypyridinoline (Dpd), serum GH, and serum immunoreactive PTH were measured at baseline and months 1, 3, 6 and 12 of GH treatment. The urinary excretion of total Pyd and Dpd, standardized by the cube of height (m3) in overnight, 24-hour urine collections was not different from age-matched healthy controls at baseline in either group of patients. During treatment with human recombinant GH, both pyridinium crosslinks increased above normal values, reaching a peak after one month in children with GH deficiency and later (after 3-6 months) in children with short stature. Free and total crosslink forms were correlated, and GH treatment did not affect the proportion of free to bound crosslinks. Serum concentrations of iPTH showed a moderate but not statistically significant increase. This study provides no evidence of reduced bone resorption in untreated GH deficiency or in idiopathic short stature. GH treatment induced a marked, but temporary, increase of bone resorption in both groups of patients.",
keywords = "Bone metabolism, Deoxypyridinoline, Growth hormone, PTH, Pyridinoline",
author = "Francesco Branca and A. Spagnoli and S. Cianfarani and G. Spadoni and Golden, {M. H N} and B. Boscherini and S. Valtue{\~n}a and Robins, {S. P.}",
year = "2002",
language = "English",
volume = "15",
pages = "27--34",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "1",

}

TY - JOUR

T1 - Urinary excretion of pyridinium crosslinks in short children treated with growth hormone

AU - Branca, Francesco

AU - Spagnoli, A.

AU - Cianfarani, S.

AU - Spadoni, G.

AU - Golden, M. H N

AU - Boscherini, B.

AU - Valtueña, S.

AU - Robins, S. P.

PY - 2002

Y1 - 2002

N2 - The aim of this study was to evaluate the effect of growth hormone (GH) treatment on bone resorption in children with GH deficiency and those with idiopathic short stature. The study population included seven children with subnormal spontaneous GH secretion and 13 children with idiopathic short stature, all of them pre-pubertal. Anthropometric measurements, free, protein-bound and total urinary pyridinoline (Pyd) and deoxypyridinoline (Dpd), serum GH, and serum immunoreactive PTH were measured at baseline and months 1, 3, 6 and 12 of GH treatment. The urinary excretion of total Pyd and Dpd, standardized by the cube of height (m3) in overnight, 24-hour urine collections was not different from age-matched healthy controls at baseline in either group of patients. During treatment with human recombinant GH, both pyridinium crosslinks increased above normal values, reaching a peak after one month in children with GH deficiency and later (after 3-6 months) in children with short stature. Free and total crosslink forms were correlated, and GH treatment did not affect the proportion of free to bound crosslinks. Serum concentrations of iPTH showed a moderate but not statistically significant increase. This study provides no evidence of reduced bone resorption in untreated GH deficiency or in idiopathic short stature. GH treatment induced a marked, but temporary, increase of bone resorption in both groups of patients.

AB - The aim of this study was to evaluate the effect of growth hormone (GH) treatment on bone resorption in children with GH deficiency and those with idiopathic short stature. The study population included seven children with subnormal spontaneous GH secretion and 13 children with idiopathic short stature, all of them pre-pubertal. Anthropometric measurements, free, protein-bound and total urinary pyridinoline (Pyd) and deoxypyridinoline (Dpd), serum GH, and serum immunoreactive PTH were measured at baseline and months 1, 3, 6 and 12 of GH treatment. The urinary excretion of total Pyd and Dpd, standardized by the cube of height (m3) in overnight, 24-hour urine collections was not different from age-matched healthy controls at baseline in either group of patients. During treatment with human recombinant GH, both pyridinium crosslinks increased above normal values, reaching a peak after one month in children with GH deficiency and later (after 3-6 months) in children with short stature. Free and total crosslink forms were correlated, and GH treatment did not affect the proportion of free to bound crosslinks. Serum concentrations of iPTH showed a moderate but not statistically significant increase. This study provides no evidence of reduced bone resorption in untreated GH deficiency or in idiopathic short stature. GH treatment induced a marked, but temporary, increase of bone resorption in both groups of patients.

KW - Bone metabolism

KW - Deoxypyridinoline

KW - Growth hormone

KW - PTH

KW - Pyridinoline

UR - http://www.scopus.com/inward/record.url?scp=0036003802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036003802&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 27

EP - 34

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 1

ER -